Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

831118

registered interest
date	26/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Liothyronine
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many reports have been made by prescribers or patients to the Medicines and Healthcare products Regulatory Agency on unlicensed liothyronine.
tabling member constituency	Twickenham
tabling member printed	Sir Vince Cable
uin	125126
answer	answer is ministerial correction date of answer 31/01/2018 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) have received 124 spontaneous reports of suspected adverse drug reactions (ADRs) via the Yellow Card Scheme from prescribers and patients in association with liothyronine in the United Kingdom as of 28 January 2018. The MHRA have not received any spontaneous cases where the reporter has stated their liothyronine is unlicensed.</p><p> </p><p>Of the 124 reports, six relate to a brand of liothyronine that is not licensed in the UK. However, it is important to note that patients may have been prescribed a medication while in a foreign country; therefore, a report of a foreign brand cannot be assumed as unlicensed use. Furthermore, while reporters are requested to provide as much detail as possible, detail of the medicinal brand or license is not a compulsory reporting criteria. Therefore, this information is not always provided.</p><p> </p><p>Yellow Card data should not be used as an indicator of the frequency of suspected ADRs to medicines. The level of ADR reporting may fluctuate over time due to a variety of reasons such as a medicine being new, stimulated interest/publicity and variations in exposure to the medicine.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 31/01/2018 14:09:34 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	207 label Biography information for Sir Vince Cable

831119

registered interest
date	26/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Liothyronine
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department has taken under the Health Service Medical Supplies (Costs) Act 2017 to collect information on the Concordia/Amdipharm Mercury Group and liothyronine.
tabling member constituency	Twickenham
tabling member printed	Sir Vince Cable
uin	125127
answer	answer is ministerial correction date of answer 31/01/2018 answer text <p>The information powers in the Health Service Medical Supplies (Costs) Act 2017 can only be implemented by regulations. At the end of last year the Department consulted on those regulations and we are currently analysing the responses to that consultation.</p><p> </p><p>The Competition and Markets Authority has provisionally found that that Concordia abused its dominant position to overcharge the National Health Service by millions for liothyronine tablets. A provisional decision does not necessarily lead to an infringement decision. Where companies have breached competition law, the Department will seek damages and invest that money back into the NHS.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 31/01/2018 16:25:09 answering member 4067 label Biography information for Steve Brine
tabling member	207 label Biography information for Sir Vince Cable

831184

registered interest
date	26/01/2018
answering body	Ministry of Justice
answering dept id	54
answering dept short name	Justice
answering dept sort name	Justice
hansard heading	Prisoners' Release: Males
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Justice, what proportion of male prisoners serving Indefinite Public Protection sentences were released following (a) a period in Category D open conditions, (b) a period in Category C conditions and (c) directly from a Category A or B prison in each of the last five years.
tabling member constituency	Twickenham
tabling member printed	Sir Vince Cable
uin	125192
answer	answer is ministerial correction date of answer 31/01/2018 answer text <p>The information requested could only be obtained at disproportionate cost.</p><p> </p><p>Prisoners are categorised based on an individual assessment of risk of escape or abscond, of harm to the public in such an event, and any risk to the security and safety of the prison and those within it.</p><p> </p><p>Progression towards release for those serving Imprisonment for Public Protection (IPP) sentences can take a number of routes. Open conditions offer a means to test prisoners in conditions closer to those in the community, and IPP prisoners will only be assessed as suitable for location in such prisons following a robust risk assessment. They can be removed back to closed conditions immediately at any time.</p><p> </p><p>Our priority remains the protection of the public, and this is reflected in the work HM Prison and Probation Service undertake with IPP prisoners prior to and following their release.</p><p> </p><p>No changes have been made to the IPP release test, and the independent Parole Board will continue to rigorously assess all tariff-expired IPP prisoners, in order as to determine they are safe to be released.</p> answering member constituency Penrith and The Border answering member printed Rory Stewart grouped question UIN 125193 question first answered 31/01/2018 16:05:21 answering member 4137 label Biography information for Rory Stewart
tabling member	207 label Biography information for Sir Vince Cable

831185

registered interest
date	26/01/2018
answering body	Ministry of Justice
answering dept id	54
answering dept short name	Justice
answering dept sort name	Justice
hansard heading	Prisoners' Release: Females
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Justice what proportion of female prisoners serving Indefinite Public Protection sentences were released following (a) a period in open conditions, (b) a period in closed conditions and (c) directly from a Category A or restricted status prison in each of the last five years.
tabling member constituency	Twickenham
tabling member printed	Sir Vince Cable
uin	125193
answer	answer is ministerial correction date of answer 31/01/2018 answer text <p>The information requested could only be obtained at disproportionate cost.</p><p> </p><p>Prisoners are categorised based on an individual assessment of risk of escape or abscond, of harm to the public in such an event, and any risk to the security and safety of the prison and those within it.</p><p> </p><p>Progression towards release for those serving Imprisonment for Public Protection (IPP) sentences can take a number of routes. Open conditions offer a means to test prisoners in conditions closer to those in the community, and IPP prisoners will only be assessed as suitable for location in such prisons following a robust risk assessment. They can be removed back to closed conditions immediately at any time.</p><p> </p><p>Our priority remains the protection of the public, and this is reflected in the work HM Prison and Probation Service undertake with IPP prisoners prior to and following their release.</p><p> </p><p>No changes have been made to the IPP release test, and the independent Parole Board will continue to rigorously assess all tariff-expired IPP prisoners, in order as to determine they are safe to be released.</p> answering member constituency Penrith and The Border answering member printed Rory Stewart grouped question UIN 125192 question first answered 31/01/2018 16:05:21 answering member 4137 label Biography information for Rory Stewart
tabling member	207 label Biography information for Sir Vince Cable

831187

registered interest
date	26/01/2018
answering body	Ministry of Justice
answering dept id	54
answering dept short name	Justice
answering dept sort name	Justice
hansard heading	Parole
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Justice what his policy is on the publication of the reasons for Parole Board decisions.
tabling member constituency	Twickenham
tabling member printed	Sir Vince Cable
uin	125195
answer	answer is ministerial correction date of answer 05/02/2018 answer text <p>Publication of the reasons for Parole Board decisions is currently prohibited by law.</p><p>However, My Right Honourable Friend, the Secretary of State has announced that there will be a review of transparency in the parole process. On 19 January, he further announced that the review of transparency should consider the law, policy, guidance and practice relating to challenges to Parole Board decision making.</p><p>The terms of reference for the review can be found at: <a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/674955/pb-review-terms-of-reference.pdf" target="_blank">www.gov.uk/government/uploads/system/uploads/attachment_data/file/674955/pb-review-terms-of-reference.pdf</a></p><p>The intention is that the review will be completed before Easter.</p> answering member constituency Penrith and The Border answering member printed Rory Stewart question first answered 05/02/2018 17:00:18 answering member 4137 label Biography information for Rory Stewart
tabling member	207 label Biography information for Sir Vince Cable

830539

registered interest
date	25/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Liothyronine
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what estimate he has made of the money accrued to the public purse in relation to liothyronine under the (a) the voluntary Pharmaceutical Price Regulation Scheme and (b) the statutory scheme; and when those payments were made.
tabling member constituency	Twickenham
tabling member printed	Sir Vince Cable
uin	125067
answer	answer is ministerial correction date of answer 30/01/2018 answer text <p>The costs of branded medicines are controlled by the Pharmaceutical Price Regulation Scheme and the statutory scheme for branded medicines. Liothyronine is an unbranded generic medicine. For unbranded generic medicines, the Department encourages competition between suppliers to keep prices down. In primary care, community pharmacies are incentivised to source products at the lowest possible cost and in secondary care, competitive tenders ensure value-for-money to the National Health Service.</p><p> </p><p>Liothyronine is currently the subject of an investigation by the Competition and Markets Authority, which has provisionally found that the single supplier of the product abused its dominant position to overcharge the NHS by millions for liothyronine tablets. A provisional decision does not necessarily lead to an infringement decision. Where companies have breached competition law, the Department will seek damages and invest that money back into the NHS.</p><p> </p><p>Medicines legislation requires that only medicines licensed for use in the United Kingdom can be marketed in the UK.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 125070 question first answered 30/01/2018 17:14:17 answering member 4067 label Biography information for Steve Brine
tabling member	207 label Biography information for Sir Vince Cable

830540

registered interest
date	25/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Liothyronine
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the effect on the level of caseloads of consultant endocrinologists as a result of changes to the prescription of liothyronine.
tabling member constituency	Twickenham
tabling member printed	Sir Vince Cable
uin	125068
answer	answer is ministerial correction date of answer 30/01/2018 answer text <p>The Department has made no assessment. It is for local clinical commissioning groups in conjunction with local providers to make decisions on implementing NHS England’s guidance on liothyronine and, as part of their decision making, to determine the resources available to implement any change.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 30/01/2018 17:10:32 answering member 4067 label Biography information for Steve Brine
tabling member	207 label Biography information for Sir Vince Cable

830542

registered interest
date	25/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Liothyronine
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether he plans to reduce the cost of liothyronine by procuring the drug from foreign suppliers; and if he will make a statement.
tabling member constituency	Twickenham
tabling member printed	Sir Vince Cable
uin	125070
answer	answer is ministerial correction date of answer 30/01/2018 answer text <p>The costs of branded medicines are controlled by the Pharmaceutical Price Regulation Scheme and the statutory scheme for branded medicines. Liothyronine is an unbranded generic medicine. For unbranded generic medicines, the Department encourages competition between suppliers to keep prices down. In primary care, community pharmacies are incentivised to source products at the lowest possible cost and in secondary care, competitive tenders ensure value-for-money to the National Health Service.</p><p> </p><p>Liothyronine is currently the subject of an investigation by the Competition and Markets Authority, which has provisionally found that the single supplier of the product abused its dominant position to overcharge the NHS by millions for liothyronine tablets. A provisional decision does not necessarily lead to an infringement decision. Where companies have breached competition law, the Department will seek damages and invest that money back into the NHS.</p><p> </p><p>Medicines legislation requires that only medicines licensed for use in the United Kingdom can be marketed in the UK.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 125067 question first answered 30/01/2018 17:14:17 answering member 4067 label Biography information for Steve Brine
tabling member	207 label Biography information for Sir Vince Cable

827954

registered interest
date	22/01/2018
answering body	Department for Transport
answering dept id	27
answering dept short name	Transport
answering dept sort name	Transport
hansard heading	Aviation: Carbon Emissions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Transport, what targets his Department has set for carbon emissions in the aviation sector in (a) 2030, (b) 2040 and (c) 2050.
tabling member constituency	Twickenham
tabling member printed	Sir Vince Cable
uin	123914
answer	answer is ministerial correction date of answer 30/01/2018 answer text <p>The Government has set no specific emissions target for the UK aviation sector in any of the three years named.</p><p> </p><p>While domestic aviation is included, emissions from international aviation are currently excluded from the legally-binding 2050 target which was set by the Climate Change Act 2008, and from the five carbon budgets which have been set to date (covering the period up to 2032).</p><p> </p><p>However, the UK’s carbon budgets have been set at a level that accounts for international aviation and shipping emissions, so that the UK is on a trajectory that could be consistent with a 2050 target that includes these emissions.</p><p> </p><p>Last year the UK was instrumental in reaching a ground-breaking international agreement at the International Civil Aviation Organisation on how to limit the emissions from the sector.</p><p> </p><p>The Government will now set out its strategic approach to the aviation sector in a series of consultations leading to the publication of a new Aviation Strategy for the UK in 2019.</p><p> </p><p>The Strategy will consider what the best approach and combination of policy measures are at the international and domestic level to ensure we effectively address carbon emissions from aviation.</p><p> </p> answering member constituency Hereford and South Herefordshire answering member printed Jesse Norman question first answered 30/01/2018 16:55:39 answering member 3991 label Biography information for Jesse Norman
tabling member	207 label Biography information for Sir Vince Cable

827981

registered interest
date	22/01/2018
answering body	Cabinet Office
answering dept id	53
answering dept short name	Cabinet Office
answering dept sort name	Cabinet Office
hansard heading	Carillion
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Minister for the Cabinet Office, what assessment he has made of Carillion’s compliance with the Prompt Payment Code.
tabling member constituency	Twickenham
tabling member printed	Sir Vince Cable
uin	123941
answer	answer is ministerial correction date of answer 14/03/2018 answer text <p>The Prompt Payment Code is monitored by the Prompt Payment Code Compliance Board, under the auspices of the Chartered Institute of Credit Management.</p> answering member constituency Hertsmere answering member printed Oliver Dowden question first answered 14/03/2018 14:06:58 answering member 4441 label Biography information for Oliver Dowden previous answer version 37128 answering member constituency Hertsmere answering member printed Oliver Dowden answering member 4441 label Biography information for Oliver Dowden
tabling member	207 label Biography information for Sir Vince Cable